{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "17879735", "DateCompleted": {"Year": "2009", "Month": "01", "Day": "05"}, "DateRevised": {"Year": "2018", "Month": "12", "Day": "01"}, "Article": {"ArticleDate": [], "Language": ["chi"], "ELocationID": [], "Journal": {"ISSN": "1001-5302", "JournalIssue": {"Volume": "32", "Issue": "13", "PubDate": {"Year": "2007", "Month": "Jul"}}, "Title": "Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica", "ISOAbbreviation": "Zhongguo Zhong Yao Za Zhi"}, "ArticleTitle": "[Roles of potassium channel in effects of resveratrol on isolated myocardial contractility and heart rate research in guinea pig].", "Pagination": {"StartPage": "1317", "EndPage": "1319", "MedlinePgn": "1317-9"}, "Abstract": {"AbstractText": ["To study the effects of resvaratrol derivatives on spontaneous HR and CF of isolated guinea pig atrium.", "The dose-effect curve of resvaratrol was observed. The possible mechanism of potassium channels responsible for changes of CF and HR after administering with resvaratrol was measured.", "Resvaratrol reduced the spontaneous HR and weakened the CF in a dose-dependent manner ranging from 10(-6) to 3 x 10(-4) mol x L(-1) (P < 0.05). As compared with Res group, the effects were partly blocked by Gli (P < 0.05) and TEA (P < 0.01), but not blocked by 4-AP, BaCl2, Atropine.", "Resvaratrol can induce negative chronotropic action and negative (inotropic action. The mechanism(s) may relate to the opening of K(ATP) and Kc(Ca)."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Physiology, Basic Medical College, Hebei Medical University, Shijiazhuang 050091, China. ccwgy@163.com"}], "Identifier": [], "LastName": "Wang", "ForeName": "Gui-ying", "Initials": "GY"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Song", "ForeName": "Cui-miao", "Initials": "CM"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zhang", "ForeName": "Li-nan", "Initials": "LN"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Li", "ForeName": "Qian", "Initials": "Q"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Yue", "ForeName": "Hua", "Initials": "H"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Feng", "ForeName": "Jing-kun", "Initials": "JK"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Wang", "ForeName": "Na", "Initials": "N"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "China", "MedlineTA": "Zhongguo Zhong Yao Za Zhi", "NlmUniqueID": "8913656", "ISSNLinking": "1001-5302"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Barium Compounds"}, {"RegistryNumber": "0", "NameOfSubstance": "Cardiotonic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Chlorides"}, {"RegistryNumber": "0", "NameOfSubstance": "KATP Channels"}, {"RegistryNumber": "0", "NameOfSubstance": "Potassium Channel Blockers"}, {"RegistryNumber": "0", "NameOfSubstance": "Potassium Channels, Calcium-Activated"}, {"RegistryNumber": "0", "NameOfSubstance": "Potassium Channels, Inwardly Rectifying"}, {"RegistryNumber": "0", "NameOfSubstance": "Stilbenes"}, {"RegistryNumber": "0VK51DA1T2", "NameOfSubstance": "barium chloride"}, {"RegistryNumber": "66-40-0", "NameOfSubstance": "Tetraethylammonium"}, {"RegistryNumber": "Q369O8926L", "NameOfSubstance": "Resveratrol"}, {"RegistryNumber": "SX6K58TVWC", "NameOfSubstance": "Glyburide"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Barium Compounds"}, {"QualifierName": ["administration & dosage", "isolation & purification", "pharmacology"], "DescriptorName": "Cardiotonic Agents"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Chlorides"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Glyburide"}, {"QualifierName": [], "DescriptorName": "Guinea Pigs"}, {"QualifierName": ["drug effects"], "DescriptorName": "Heart Rate"}, {"QualifierName": [], "DescriptorName": "In Vitro Techniques"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "KATP Channels"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug effects"], "DescriptorName": "Myocardial Contraction"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Potassium Channel Blockers"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Potassium Channels, Calcium-Activated"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Potassium Channels, Inwardly Rectifying"}, {"QualifierName": [], "DescriptorName": "Resveratrol"}, {"QualifierName": ["administration & dosage", "isolation & purification", "pharmacology"], "DescriptorName": "Stilbenes"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Tetraethylammonium"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2007", "Month": "9", "Day": "21", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "1", "Day": "6", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "9", "Day": "21", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["17879735"]}}], "PubmedBookArticle": []}